As members of the newly established women’s health interest group in the European Parliament, the persisting failure to consider the health needs of women, in all their diversity is an issue that is high on our agenda. A recent publication highlights that maternal health conditions such as preeclampsia/ eclampsia and postpartum haemorrhage received less than 1% of European sexual & reproductive health R&D funding between 2018 and 2020. Europe accounts for only 13% of the global funding for sexual and reproductive health R&D, with investments split evenly between public and private organisations. ADVERTISEMENTAs simultaneously converging crises threaten to compound inequalities and with growing attention on the need to address the unmet medical needs of women, the EU must step up its efforts to support global women’s health R&D. In delivering better health outcomes for women, such investments will contribute to improved societal wellbeing, for the benefit of us all.
